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Interleukin-21 (IL-21) is a pleiotropic cytokine that
induces expression of transcription factor BLIMP1
(encoded by Prdm1), which regulates plasma cell
differentiation and T cell homeostasis. We identified
an IL-21 response element downstream of Prdm1
that binds the transcription factors STAT3 and IRF4,
which are required for optimal Prdm1 expression.
Genome-wide ChIP-Seq mapping of STAT3- and
IRF4-binding sites showed that most regions with
IL-21-induced STAT3 binding also bound IRF4
invivoand furthermore revealed that thenoncanonical
TTCnnnTAA GAS motif critical in Prdm1 was broadly
used for STAT3 binding. Comparing genome-wide
expression array data to binding sites revealed that
most IL-21-regulated genes were associated with
combined STAT3-IRF4 sites rather than pure STAT3
sites. Correspondingly, ChIP-Seq analysis of Irf4/
Tcells showedgreatlydiminishedSTAT3bindingafter
IL-21 treatment, and Irf4/mice showed impaired IL-
21-induced Tfh cell differentiation in vivo. These
results reveal broad cooperative gene regulation by
STAT3 and IRF4.
INTRODUCTION
B lymphocyte-induced maturation protein-1 (BLIMP1) is a tran-
scriptional repressor that was discovered as a zinc finger protein
expressed upon plasmacytic differentiation of the Bcl-1 B cell
lymphoma line (Turner et al., 1994). BLIMP1 is encoded by the
PRDM1 gene in humans and the Prdm1 gene in mice. BLIMP1
regulates terminal differentiation of plasma cells in which it
represses the expression of the Bcl6 and Pax5 genes (Martins
and Calame, 2008); BCL6 in turn can repress Prdm1 expression
(Shaffer et al., 2000). BLIMP1 has been most thoroughly studied
in a B cell context, but it is also expressed in T cells, granulo-
cytes, macrophages, epithelial cells, and germ cells and regu-Ilates T cell homeostasis and peripheral tolerance (Kallies et al.,
2006; Martins et al., 2006; Ohinata et al., 2005).
Interleukin-21 (IL-21) is a type I cytokine produced after T cell
activation that is most related to IL-2, IL-4, and IL-15 (Parrish-
Novak et al., 2000; Spolski and Leonard, 2008). The IL-21
receptor was discovered as an orphan receptor (Ozaki et al.,
2000; Parrish-Novak et al., 2000). Like IL-2, IL-4, IL-7, IL-9, and
IL-15, IL-21 shares the common cytokine receptor g chain, gc,
as a critical receptor component (Spolski and Leonard, 2008).
gc is encoded by the IL2RG gene, mutation of which results in
X-linked severe combined immunodeficiency in humans,
a disease in which T and NK cells are absent and B cells are
present but nonfunctional (Leonard, 2001; Noguchi et al.,
1993). IL-21 receptors are expressed by T cells, B cells, NK cells,
myeloid cells, and keratinocytes, corresponding to pleiotropic
actions of IL-21 on multiple lineages. IL-21 can act as a comito-
gen for T cells (Parrish-Novak et al., 2000), can potently drive
CD8+ T cell expansion when combined with IL-7 or IL-15 (Zeng
et al., 2005), and promotes the differentiation of T helper
17 (Th17) CD4+ T cells (Spolski and Leonard, 2008) and develop-
ment of T follicular helper (Tfh) cells (Nurieva et al., 2008;
Vogelzang et al., 2008). Within the B cell lineage, IL-21 critically
regulates immunoglobulin production, particularly IgG1, and
mice lacking expression of both IL-4 and IL-21R exhibit defective
germinal center development and pan-hypogammaglobuline-
mia, which is likely to explain the B cell phenotype in humans
with XSCID (Ozaki et al., 2002). Moreover, IL-21 potently induces
BLIMP1 and plasma cell differentiation (Ozaki et al., 2004).
We have elucidated the molecular basis for IL-21-mediated
BLIMP1 induction by finding an IL-21 response element 30 of
the Prdm1 gene whose activity requires both STAT3 and IRF4.
STAT3 (signal transducer and activator of transcription 3) and
IRF4 (interferon regulatory factor-4) mediate signaling in
response to a range of cytokines, including IL-21 (Zeng et al.,
2007; Huber et al., 2008). IRF4 is a lymphocyte-restricted tran-
scription factor that is part of a family of DNA-binding proteins
critical for the function and homeostasis of mature B and
T cells, as well as for the development of subpopulations of
dendritic cells (Gabriele and Ozato, 2007; Tamura et al., 2008).
We identified a functional cooperation between STAT3 andmmunity 31, 941–952, December 18, 2009 ª2009 Elsevier Inc. 941
A B
0
1
2
3
4
M12CH1
2
Bcl-
1
NFS
201
NFS
202
Cell line
Pr
dm
1/
18
S
5
Ctrl
IL-21
0
1
2
Anti-CD40
Anti-IgM-Fab
+
Pr
dm
1/
18
S
-
+
+
-
-
Pre-activation
C
IL-21 +-
BLIMP1
Actin
XX
KSS K
K K
R1-10.2Kb 29.4Kb
28.0Kb22.3Kb
Exon 12 3 4 5 67 8
pGL4-pro
2Kb
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
D
E
F
G
H
Ctrl
IL-21
Reporter
RL
U
pGL
3
pGL
3-pr
o R1 R2 R3 R4 R5 R6 R7
0
1
2
3
R8 R9 R10
Ctrl
IL-21
0
20RL
U
40 NFS201
0
20
40
RL
U
60
Splenic B cells
pGL
4
pGL
4-pr
o
R11
Reporter
Ctrl
IL-21
Ctrl
IL-21
R15
R14
R13
R12
R11
pGL4-pro
pGL4
LucP
LucP
LucP
LucP
LucP
LucP
Luc
LucPR16
LucP
LucP
LucP
LucP
LucP
LucP
LucP
LucP
LucP
LucP
LucP
LucP
LucP
R21
R20
R19
R18
R17
R22
R27
R26
R25
R24
R23
R28
R29
22.3Kb 28.0Kb
26.0Kb
26.4Kb
26.1Kb
26.5Kb
26.0Kb 26.5Kb
0 40 80 120 160
RLU
Ctrl
IL-21
R33
R32
R31
R30
R26
pGL4-pro
pGL4
LucP
LucP
LucP
LucP
LucP
LucP
Luc
LucPR34
LucP
LucP
LucP
LucP
LucP
LucP
R35
R38
R37
R36
R39
R40
26.0Kb 26.5Kb
26.2Kb 26.4Kb
26.3Kb
26.2Kb
26.4Kb
26.3Kb
0 40 80 120
X9.6
X12.7
X10.4
X1.1
X2.4
RLU
X6.3
Ctrl
IL-21
Figure 1. Characterization of an IL-21
Response Element 30 of the Prdm1 Gene
(A) IL-21 induces Prdm1 gene expression. Prdm1
mRNA (means ± SEM of R3 independent experi-
ments, total combined samples R4) was deter-
mined by quantitative RT-PCR 6 hr after treatment
with 50 ng/ml IL-21.
(B) Cells were activated with 1 mg/ml anti-CD40
and/or 3 mg/ml anti-IgM-Fab for 3 days, rested
24 hr, and treated with 100 ng/ml IL-21. Prdm1
mRNA (means ± SEM of two independent experi-
ments, total combined samples = 4) was deter-
mined 24 hr later by quantitative RT-PCR.
(C) Cells were activated with 1 mg/ml anti-CD40 for
3 days, rested for 24 hr, and treated with 100 ng/ml
IL-21 for 24 hr and immunoblotted with antibodies
to BLIMP1 or actin. Representative results of three
independent experiments.
(D) Schematic of the Prdm1 gene (defined by
NM_007548 version 2; version 3 of May 2008
starts 61 bp downstream and lacks the 79 bp
second exon) and locations of luciferase reporter
constructs. pGL4-pro, minimal promoter (972
to +183) reporter; K, KpnI; X, XhoI; S, SmaI; open
triangle is the luciferase insertion site in exon 1
for R1, R8, R9, and R10.
(E) Luciferase assays in NFS201 cells were per-
formed 18 hr after treatment with 50 ng/ml IL-21.
(F) Shown is luciferase activity 6 hr after treatment
with 50 ng/ml IL-21 for NFS201 (means ± SEM of
R4 independent experiments, total combined
samplesR6) and with 100 ng/ml IL-21 for splenic
B cells (means ± SEM ofR2 independent experi-
ments, total combined samplesR4).
(G and H) More detailed mapping of the Prdm1
IL-21 response element in preactivated splenic B
cells. Shown is luciferase activity 6 hr after treat-
ment with 100 ng/ml IL-21 (means ± SEM of R3
independent experiments, total combined
samplesR6).
Immunity
Cooperativity of STAT3 and IRF4IRF4 in IL-21-induced Prdm1 expression, extending the range of
known actions for IRF4. Moreover, Solexa-based ChIP-Seq
genome-wide analyses revealed that most genomic areas
binding STAT3 after IL-21 treatment also constitutively bind
IRF4 and that there was greatly diminished STAT3 binding in
the absence of IRF4. We demonstrate that the expression of
other IL-21-regulated genes also depends on both STAT3 and
IRF4, revealing the broad functional cooperation of these tran-
scription factors. Finally, we showed that the Prdm1 IL-21
response element uses a single-nucleotide variant (TTCnnnTAA)
of the canonical TTCnnnGAA STAT3 motif, and this variant is
a broadly used GAS motif in the genome.
RESULTS
IL-21 Rapidly Induces Prdm1 Gene Expression
We previously showed that IL-21 can induce BLIMP1 expression
(Ozaki et al., 2004), and indeed, IL-21 can induce Prdm1 expres-
sion in multiple B lymphoma lines (Figure 1A). When primary942 Immunity 31, 941–952, December 18, 2009 ª2009 Elsevier Inc.splenic B cells were preactivated with anti-CD40, with or without
anti-IgM, and rested, subsequent IL-21-induced Prdm1 expres-
sionwas higher in cells preactivatedwithout anti-IgM (Figure 1B).
IL-21 also induced BLIMP1 expression in preactivated B cells
(Figure 1C). Induction of Prdm1 mRNA was seen by 1 hr, with
peak mRNA expression typically at 24 hr (Figure S1A and S1B
available online). LPS also induced Prdm1 expression, whereas
IL-4 did not (Figure S1B). IL-21 reproducibly induced Prdm1
gene expression slightly more quickly than did LPS, although
LPS was more potent in its effect at 48 hr (Figure S1B).
An IL-21 Response Element Is 30 of the Prdm1 Gene
To identify an IL-21-responsive region, we transfected NFS201
cells with a series of Prdm1 luciferase reporter constructs
(Figure 1D). A ‘‘full-length’’ construct denoted R1 (reporter
construct 1) extending from 10.2 to +29.4 kb relative to the
main transcription start site (TSS) exhibited IL-21-induced
activity, but a series of smaller constructs, R2–R7, did not
(Figures 1D and 1E). We digested R1 with restriction enzymes
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Figure 2. STAT3 and IRF4 Bind to the Prdm1 IL-21 Response
Element
(A) DNA sequence of the 212 bp (26,237 to 26,448 region relative to the TSS)
R37 construct containing the IL-21 response element. The STAT3-binding
motif is underlined, IRF4 and IRF8-binding motifs are boxed, and probes #1,
#2, and #3 are indicated.
(B) EMSAs with nuclear extracts from NFS201 cells treated for 7 hr with 50 ng/
ml IL-21. The solid and open arrows indicate IL-21-induced complexes, with
the solid arrow corresponding to the STAT3-DNA complex. The open and
closed circles indicate the supershifted STAT3 and IRF4 complexes, respec-
tively. The WT probe is probe #1 in (A).
(C) EMSAswere performedwith probes #2 and #3 (bold and italic sequences in
A) with NFS201 nuclear extracts. The solid arrowhead indicates an IL-21-
induced complex, the closed circle indicates supershifted IRF4-DNA com-
plexes, and the open arrowhead indicates a supershifted IRF8-DNA complex.
Immunity
Cooperativity of STAT3 and IRF4
Ito generate internal deletion constructs R8, R9, and R10
(Figure 1D). Of these, only R9 exhibited IL-21-induced luciferase
activity (Figure 1E), indicating that the IL-21 response region is
between 22.3 and 28.0 kb. Indeed, construct R11 containing
this specific region 50 to the Prdm1minimal promoter (Figure 1D)
responded to IL-21 in NFS201 cells and primary splenic B cells
(Figure 1F).
We therefore generated deletionmutants of R11 (Figure 1G). 50
deletion to 26.0 kb (constructs R12 to R17) exhibited IL-21-
induced activity, but further deletion (R18 andR19) greatly dimin-
ished IL-21-induced activity. With 30 deletion mutants, R22
retained activity, but R20 and R21 did not. Together, the activi-
ties of R17 and R22 indicated the critical role of the 26 to 26.5
kb region. Moreover, R23 and R25, which lack this region,
were inactive, whereas R24 and R26 reporters, which span this
region, potently responded to IL-21 (Figure 1G). Furthermore,
deletion of the 26-26.5 kb region from R11 to yield R27 abro-
gated IL-21-induced activity (Figure 1G). To refine the mapping,
we generated deletion mutants of R26 (Figure 1H). 50 deletion to
26.2 kb (R31) retained activity but deletion to 26.3 kb (R32) elim-
inated activity. 30 deletion to 26.4 kb (R33) lowered basal activity
(open bar) but not inducibility (closed bar), whereas deletion to
26.3 kb (R34) or beyond (R35) eliminated IL-21-induced activity.
Thus, both the 26.2–26.3 kb and 26.3–26.4 kb regions were
essential, and R36 and R37, which span the 26.2 to 26.4 kb
region, both exhibited substantial activity, whereas smaller frag-
ments (R38, R39, and R40) had greatly decreased activity. These
data were consistent with two factors binding within the 212 bp
region (extending from +4678 to +4889 relative to the ATTAAA
polyadenylation signal of the Prdm1 gene; see NM_007548.3),
one in the R38 region and one in the R40 region, to mediate
IL-21-induced Prdm1 expression.
STAT3 and IRF4 Bind to the Prdm1 IL-21
Response Element In Vivo
IL-21 can activate STAT1, STAT3, and STAT5, with STAT3 being
the most important for IL-21 signaling (Diehl et al., 2008; Zeng
et al., 2007). We used transcription-factor-binding prediction
software (MatInspector) to identify potential g-interferon-acti-
vated sequence (GAS) motifs that can bind these STATs (Levy
and Darnell, 2002). Canonical GAS motifs have a TTCnnnGAA
sequence, but the 212 bp Prdm1 IL-21 response element has
a single-nucleotide variant TTCCAGTAA motif (underlined in
Figure 2A). Electrophoretic mobility shift assays (EMSAs) with
NFS201 nuclear extracts and aWT probe (probe #1 in Figure 2A)
revealed an IL-21-induced complex (Figure 2B, lane 2, solid
arrow), but not when the motif was mutated to agaCAGTAA
(lane 4). The complex was super-shifted by anti-STAT3 but not
by antibodies to STAT1, STAT5A, or STAT5B (lanes 5–8). IL-21
also induced formation of a faster mobility complex (lane 2,
open arrow) whose intensity was enhanced with the mutant
probe (lane 4). Examination of the DNA sequence revealed
a putative IRF-binding motif (Tamura et al., 2008) (TTTC, boxed
in Figure 2A) immediately 30 of the STAT3-binding site. Indeed,(D) ChIP was performed with crosslinked splenic B cell lysates prepared
30 min after treatment with 100 ng/ml IL-21 (means ± SEM). Input was deter-
mined by quantitative PCR. Shown are representative results from two
(B and C) or three (D) independent experiments.
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Figure 3. STAT3 and IRF4 Mediate IL-21-
Induced Prdm1 Expression in B Cells
(A) Sequences for STAT3 and IRF4-binding motif
mutants in the R37 reporter.
(B) Luciferase assays were performed with WT
or mutated R37 constructs shown in (A). Shown
is luciferase activity 6 hr after treatment with
100 ng/ml IL-21 (means ± SEM of R3 indepen-
dent experiments, total combined samplesR 6).
(C) Prdm1 mRNA expression (means ± SEM of
two independent experiments, total combined
samples = 4) was determined in preactivated
splenic B cells by quantitative RT-PCR 24 and
48 hr after treatment with 100 ng/ml IL-21.
(D) Shown is luciferase activity of the R37
construct 6 hr after treatment with 100 ng/ml
IL-21 (means ± SEM of two independent experi-
ments, total combined samples = 4).
(E) IL-21 receptor expression in preactivated and
rested Stat3-deficient B cells (dashed line). The
solid line refers to WT mice. The isotype antibody
control is shown in gray.
(F) Prdm1 and Pim1 mRNA expression (means ±
SEM of R3 independent experiments, total com-
binedsamplesR4)wasdeterminedbyquantitative
RT-PCR 24 hr after treatmentwith 100 ng/ml IL-21.
(G) IL-21 receptor expression of Irf4/ B cells
(dashed line) and WT control cells (solid line)
was determined. The isotype antibody control is
shown in gray.
(H) Splenic B cells were treated with 100 ng/ml
IL-21 (means ± SEM of two independent experi-
ments, total combined samples = 4) and Irf4
expression was determined.
(I) Prdm1 mRNA expression of IL-21 stimulated
cells expressing PU.1 (Sfpi1f/f-Cre/) or lacking
PU.1 (Sfpi1f/f-Cre/+) was determined (means ±
SEM of two independent experiments, total
combined samples R 4).
(J) IL-21 receptor expression of PU.1-deficient B
cells (dashed line) and WT control (solid line). The
isotype antibody control is shown in gray. In (C)
and (D), *p < 0.05 (compared with IL-21-treated
WT control mice). In (H), *p < 0.05 for IL-21-treated
versus Ctrl.
Immunity
Cooperativity of STAT3 and IRF4anti-IRF4 super-shifted the faster complex, whereas anti-STAT3
did not (Figure 2B, lanes 9–11), indicative of IRF4 binding.
To further investigate binding to the 212 bp IL-21 response
element, we performed EMSAs with a series of 30 bp probes
spanning this region. We found IL-21-induced complexes to
two other probes, #2 and #3 (Figures 2C), which also contain
putative TTTC IRF-binding motifs (boxed in Figure 2A). When
we mutated the TTTC motifs to gagC, DNA-protein complexes
were no longer observed (Figure 2C, lanes 3 and 4 versus 1
and 2). Moreover, complex formation was blocked and/or
super-shifted by antibodies to IRF4 and IRF8. Signals were
stronger with probe #3 than #2, perhaps because the GTTTC
sequence is better than TTTTC for binding IRF4. We also tested
antibodies to PU.1, a cofactor for IRF4 (Eisenbeis et al., 1995),
but no supershift was observed (Figure 2C).
To evaluate STAT3, IRF4, and IRF8 binding in vivo, we used
splenic B cells and chromatin immunoprecipitation (ChIP).
IL-21 induced binding of STAT3 and IRF4 but not of IRF8 to944 Immunity 31, 941–952, December 18, 2009 ª2009 Elsevier Inc.the Prdm1 gene (Figure 2D), whereas none of these factors
bound to a control intronic region of the mouse b-actin (Actb)
gene (data not shown). Thus, STAT3 and IRF4 bind to the
Prdm1 response element in primary B cells in vivo.
STAT3 and IRF4 Are Critical for IL-21-Induced Prdm1
Expression in B Cells
We next studied the role of STAT3 in IL-21-induced Prdm1
expression. When we mutated the TTCCAGTAA STAT3 site to
agaCAGTAA (Mut1, Figure 3A), IL-21-induced luciferase activity
was markedly reduced (R37-Mut1 in Figure 3B). Moreover,
Prdm1 mRNA expression was lower in splenic B cells from
Stat3f/f-CD19-Cre+/ mice, which lack STAT3 (Figure 3C), and
correspondingly, IL-21-induced activity of the R37 construct
was markedly reduced in these cells (Figure 3D). Thus, STAT3
was essential for activity of the Prdm1 IL-21 response element.
IL-21 receptor expression was also slightly low in Stat3f/f-
CD19-Cre+/ B cells (Figure 3E).
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Figure 4. STAT3 and IRF4 Control IL-21-
Induced Prdm1 Expression in CD4+ T Cells
(A) T cells were preactivated with anti-CD3 plus
soluble anti-CD28, and IL-2 for 3 days and rested
for 24 hr in fresh RPMI medium, and Prdm1
mRNA in CD4+ T cells was determined by quanti-
tative RT-PCR 9, 24, and 48 hr after treatment
with IL-2, IL-4, IL-5, IL-6, IL-10, IL-21, or IFN-g
(see Experimental Procedures for details). Shown
are means ± SEM ofR5 independent experiments
(total combined samplesR10).
(B) Prdm1 mRNA expression was determined in
preactivated CD8+ T cells by quantitative RT-
PCR at the indicated times after treatment with
100 ng/ml IL-21.
(C) Preactivated splenic CD4+ and CD8+ T cells
were treated with 100 ng/ml IL-21 for 24 hr and
BLIMP1 or Actin protein levels were determined
by immunnoblotting.
(D) Luciferase assays were performed with WT or
mutated forms of R37 for STAT3 and/or IRF4-
binding motifs 6 hr after treatment of CD4+
T cells with 100 ng/ml IL-21.
(E) ChIP of STAT3 and IRF4 was performed with
splenic CD4+ T cell lysates prepared 20 min after
treatment with 100 ng/ml IL-21. Input was deter-
mined by quantitative PCR. Results are represen-
tative of three independent experiments.
(F) Prdm1 mRNA expression was measured in
splenic CD4+ T cells fromStat3f/f-Cre/ orStat3f/f-
Cre/+ mice; cells were not treated or were stimu-
latedwith IL-21. The asterisk indicates no induction
as compared to IL-21-treated Stat3f/f-Cre/ cells.
(G) IL-21R expression was measured in CD4+
T cells from Stat3-deficient (dashed line) or WT
control (solid line) mice. The isotype antibody
control is shown in gray.
(H and I) Prdm1mRNA expression was measured in WT (control), Irf4/, and Irf8/ CD4+ T cells (H) or CD8+ T cells (I) by quantitative RT-PCR 24 hr after treat-
ment with 0 or 100 ng/ml IL-21mRNA levels (means ± SEM of two independent experiments, total combined samples = 4). The asterisk indicates decreased
induction as compared to Ctrl.
(J) IL-21R expression was measured in CD4+ T cells from Irf4/ (dashed line) or WT (solid line) mice. The isotype antibody control is shown in gray.
(K) IL-21 significantly induces Irf4 expression in splenic CD4+ T cells. Cells were treated with 100 ng/ml IL-21 (means ± SEM of two independent experiments,
total combined samples = 4).
(L) CD4+ T cells were preactivated and then not stimulated or stimulated with IL-21, IL-6, or IL-10, and subsequently, lysates were immunoblotted with antibodies
to phospho-STAT3, STAT3, or Actin. A representative result from three independent experiments is shown.
(M) CD4+ T cells from Irf4+/+ or Irf4/mice were preactivated and then not stimulated or stimulated with IL-21, IL-6, or IL-10 for 1 or 6 hr. Socs3mRNA expres-
sion (means ± SEM of two independent experiments, total combined samples = 4) was determined by quantitative RT-PCR. *p < 0.05 (comparing similar
samples to cells from Irf4+/+ and Irf4/ mice).
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Cooperativity of STAT3 and IRF4We next separately mutated the IRFmotifs from TTTC to gagC
in the context of R37 (Figure 3A). The Mut2 mutation did not
affect IL-21-induced luciferase activity, whereas Mut3, Mut4,
and Mut5 (combination of Mut3 and Mut4) lowered activity, and
simultaneous mutation of Mut3, Mut4, and the GAS motif
(Mut6) dramatically decreased inducible activity (Figure 3B). We
found greatly diminished IL-21-induced Prdm1 mRNA expres-
sion in Irf4/ but not Irf8/ B cells (Figure 3F, left panel),
whereas IL-21-induced Pim1 expression was not diminished
in either Irf4/ or Irf8/ B cells (right panel). There was no
difference in IL-21R expression in Irf4/ versus WT B cells
(Figure 3G), and IL-21 slightly induced Irf4 expression
(Figure 3H). Because IRF4 and PU.1 can interact (Eisenbeis
et al., 1995; Tamura et al., 2008), we also examined the IL-21-
induced Prdm1 expression in Sfpi1f/f-CD19-Cre+/ B cells and
(Sfpi1 is the gene that encodes PU.1) found similar Prdm1Iexpression to wild-type (WT) cells (Figure 3I). IL-21R expression
in Sfpi1f/f/CD19-Cre+/ B cells was similar to that in the WT
control (Figure 3J). Thus, IRF4, but not PU.1 or IRF8, is required
for Prdm1 expression.
IL-21-Induced Prdm1 Gene Expression in T Cells
Is Dependent on STAT3 and IRF4
We next examined Prdm1 induction in preactivated splenic
T cells. Whereas IL-2, IL-5, IL-6, IL-10, and IFN-g had little if
any effect, IL-4 induced Prdm1 expression, and IL-21 was the
most potent inducer in both CD4+ (Figure 4A) and CD8+
T cells (Figure 4B), with more rapid Prdm1 induction than was
seen with IL-4. IL-21 also induced BLIMP1 protein (Figure 4C).
As in B cells, IL-21 markedly increased activity of the 212 bp
R37 reporter in T cells, and mutation of the GAS motif (Mut1)
or IRF motifs (Mut5) or both together (Mut6) decreased activitymmunity 31, 941–952, December 18, 2009 ª2009 Elsevier Inc. 945
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Figure 5. STAT3- and IRF4-Binding Sites
Colocalize
(A) Venn diagram of IRF4-binding sites before and
after IL-21 stimulation. Shown are STAT3 sites
after stimulation; the rare STAT3 sites before
IL-21 treatment were omitted.
(B) High-resolution mapping of STAT3 and IRF4
ChIP-Seq tags at the Prdm1 IL-21 response
element. The number of tags/50 bp is plotted.
The 212 bp IL-21 response element is drawn to
scale and exactly overlaps the STAT3 and two
IRF4-binding sites. Themaxima of the curves coin-
cide with the essential motifs shown in Figures 3
and 4; the sequences at these maxima are high-
lighted in blue and yellow, with DNA-bindingmotifs
for STAT3 and IRF4 boxed and underlined,
respectively. The shoulder of the largest IRF4
peak suggests a secondary binding site (gray
region).
(C) The mouse Prdm1 gene includes three alterna-
tive transcript variants a, b, and c (AceView at
NCBI). The STAT3- and IRF4-binding sites before
and after IL-21 treatment are aligned (scale bar is
10 kb and 20 tags/200 bp window vertically),
with binding sites corresponding to peaks 1–13
(Table S11). Although only one STAT3-IRF4 site
(site 12, see asterisk, shown in detail in B) was
found to regulate IL-21-mediated Prdm1 expres-
sion, several other major STAT3 peaks were
induced by IL-21, and all overlapped IRF4 peaks.
In intron 5 of variant a, site 9 strongly binds
STAT3 but weakly binds IRF4, whereas site 10,
which is 1.59 kb 30 of site 9, strongly binds IRF4
but weakly binds STAT3. Additionally, IRF4 asso-
ciated to the two promoter areas at sites 1 to 5.
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Cooperativity of STAT3 and IRF4(Figure 4D). ChIP experiments confirmed STAT3 and IRF4
binding to the IL-21 response element in splenic CD4+ T cells
(Figure 4E), with no binding of these factors to an intronic region
of the Actb gene (data not shown). IL-21-induced Prdm1
expression was abrogated in splenic Stat3-deficient CD4+
T cells (Figure 4F) and markedly diminished in CD4+ and CD8+
T cells from Irf4/ but not Irf8/ mice (Figures 4H and 4I).
IL-21R expression was not altered in Stat3-deficient and Irf4/
T cells (Figure 4G and 4J). In contrast to B cells, IL-21 markedly
induced Irf4 mRNA expression in CD4+ T cells at 1 hr
(Figure 4K). Although IL-21, IL-6, and IL-10 each activated
STAT3, IL-21 was most potent (Figure 4L), corresponding to
its more potent induction of Prdm1 (Figure 4A) and Socs3
(Figure 4M) expression. At 6 hr, IL-6-, IL-10-, and IL-21-induced
Socs3 expression was reduced in Irf4/ CD4+ T cells
(Figure 4M).
Because STAT3 and IRF4 both bind to the IL-21 response
element and functionally cooperate for Prdm1 expression, we
hypothesized that these proteins might associate. Although
we saw weak coprecipitation in some experiments, this was946 Immunity 31, 941–952, December 18, 2009 ª2009 Elsevier Inc.not reproducible (data not shown),
consistent with the lack of interaction
reported in another study that used
STAT3 as a negative control for copreci-
pitation with IRF4 (Gupta et al., 1999).Thus, if STAT3 and IRF4 interact, the association is either tran-
sient or unstable under the experimental conditions used.
STAT3 and IRF4 Often Bind to Overlapping Sites
on the Genome
Because STAT3 and IRF4 cooperatively activated the Prdm1
IL-21 response element, we investigated the extent to which
binding sites for these factors colocalized. Using ChIP followed
by Solexa-based sequencing (Chip-Seq), we mapped (see
Experimental Procedures and Supplemental Experimental
Procedures and Figures S4 and S5 for details) the STAT3- and
IRF4-binding sites on the whole genome in CD4+ T cells that
were preactivated, rested, and not treated or treated with
IL-21. A total of 4.7 to 6.3 million uniquely mapped tags were
obtained from two independent experiments that were merged
(Table S1). We identified (see Experimental Procedures) 4,422
STAT3 and 18,883 IRF4 sites, covering 1.74 Mb and 7.36 Mb
(0.07% and 0.3% of the genome), respectively. Strikingly, the
binding profiles of STAT3 and IRF4 strongly overlapped: 76%
of the STAT3-binding regions also bound IRF4 (Figure 5A). The
Immunity
Cooperativity of STAT3 and IRF4a priori probability of this level of colocalization is very low
(p < 105000). Table S2 shows for all STAT3-binding sites the
characteristics of the peaks, their coordinates on the genome,
the number of STAT3 and IRF4 tags at each site before and after
IL-21 treatment, and the list of neighboring genes, which are
candidates for regulation by STAT3 and IRF4.
As expected, IL-21 induced STAT3 binding (4397 sites after
IL-21 versus 335 before). In contrast, similar numbers of
IRF4-binding sites were seen before (14,306) and after (15,408)
IL-21 treatment, and their genome-wide pattern was partly reor-
ganized (Figures 5A). The fact that 64%of the sites where STAT3
bound after IL-21 treatment were occupied by IRF4 prior to IL-21
suggested that IRF4 might promote recruitment of STAT3, and
the strong overlap of STAT3- and IRF4-binding sites suggested
that these factors might broadly cooperate to regulate gene
expression.
High-Resolution Mapping of STAT3- and IRF4-Binding
Sites in the Prdm1 Gene
We found that the genome-wide ChIP-Seq data corroborated
and extended our characterization of the Prdm1 IL-21 response
element. STAT3 and IRF4 both bound to the 212 bp IL-21
response element (Figure 5B), and the maxima of the ChIP-
Seq tag densities lie within a few base pairs of the motifs we
had defined. The STAT3 peak coincides with the TTCCAGTAA
motif (#2 blue region in Figure 5B and sequence below) and
the two IRF4 main peaks coincide with the TTTC motif (under-
lined in the blue region) and the GTTTC motif (#3 yellow region).
A secondary IRF4-binding site (#1 gray region) was also
observed. The pattern suggests that IL-21 induces STAT3
binding and a rearrangement of IRF4 binding nearby. Interest-
ingly, additional STAT3 and IRF4 sites were found in the Prdm1
gene (Figure 5C and Table S2; see Table S10 for all IRF4-binding
sites inmouse CD4+ T cells), but their functional significance was
not indicated by our Prdm1 reporter assays (Figures 1E and 1F).
Correlation of STAT3- and IRF4-Binding Sites
with IL-21-Regulated Genes
Given the functional cooperation of STAT3 and IRF4 for IL-21-
induced Prdm1 expression, we investigated whether this
extended to other genes. We performed an Affymetrix gene
expression analysis (Figures S2 and S3 and Table S3) using
preactivated T cells induced by IL-21 for 0, 1, 6, and 24 hr.
Five biological replicas at each time point gave highly consistent
results. With a fold change of R 1.5 at p % 0.001, 2322 genes
were regulated by IL-21, which included well-recognized
STAT3-regulated genes such as Socs3 and Bcl3.
To identify which IL-21-regulated genes might be regulated by
STAT3, we identified those ‘‘within reach’’ of a STAT3-binding
site by ChIP-Seq analysis. Because transcriptional regulators
can bind upstream, within, or downstream of target genes, and
act from a distance, knowing binding-site locations does not
necessarily indicate their importance for gene regulation. Never-
theless, genes with such sites were reasonable candidates.
On the basis of the ChIP-Seq experiments, 811 of the 2322
IL-21-regulated genes (Table S4) were associated with 1682
STAT3-binding sites, or an average of approximately two
STAT3 sites per IL-21-regulated gene. Most of these sites
(1308 or 78%) also bound IRF4, and we observed a cooperativeIeffect of IRF4 on STAT3 binding and vice versa: sites binding
both STAT3 and IRF4 had on average twice as many tags for
each protein as sites binding only STAT3 or IRF4.
We next examined the location of the STAT3 and IRF4 sites
relative to the IL-21 regulated genes by using gene annotations
defined in AceView (Thierry-Mieg and Thierry-Mieg, 2006), which
includes all experimentally supported alternatively spliced tran-
scripts. STAT3-binding sites lie inside 63% of the regulated
genes, upstream of 41%, and downstream of 25% (Tables S5,
S6, and S7, respectively); this sums to >100%, reflecting the
frequent presence of several STAT3 sites in more than one loca-
tion relative to a given gene. The sites are broadly distributed, but
with a relative enrichment in the promoter area, with 14% of sites
between 2 kb 50 upstream and 1 kb downstream of the most 50
TSS (Figure S7). The broad distribution is consistent with the
ability of STATs to act at a distance, as for example is seen in
the IL2RA gene (Kim et al., 2001). Interestingly, similar to the
Prdm1 site, STAT3 sites located downstream of genes more
often exhibit IRF4 cobinding (96%, 329 of 345 sites) than sites
within (71%, 600 of 850 sites) or upstream (78%, 422 of 543 sites)
of genes.
Strikingly, 310 of the 811 IL-21 sensitive genes near a STAT3-
binding site were previously associated to a phenotype by MGI
annotation (Table S4): 199 genes (25%) have particularly inter-
esting phenotypes, given that the genetic defects affect the
immune system (180 genes) or the hematopoietic system (145
genes) or lead to carcinogenesis (44 genes), as compared to
only 5% of 33,774 genes tested on the Affymetrix chip. When
we integrated in AceView the tissues of origin of the cDNA
libraries reported in GenBank and dbEST, we found that 791 of
the 811 IL-21-regulated genes (98%) with a STAT3 site nearby
were expressed within lymphoid tissues versus 66% of genes
on the Affymetrix chip.
STAT3 and IRF4 Broadly Cooperate to Mediate
IL-21-Induced Gene Expression in CD4+ T Cells
To extend our findings, we selected a number of genes induced
>1.5-fold with colocalization of STAT3 and IRF4 binding (a list of
these genes is in Tables S5–S7). As shown in Figure 6A (open
bars), IL-21 significantly enhanced the expression of Socs3,
Bcl3, and Tha1 in CD4+ T cells from WT littermate controls, but
their induction was diminished in cells from Irf4/ mice (solid
bars) and Stat3/ mice (data not shown). This is consistent
with closely positioned STAT3- and IRF4-binding sites in these
genes (Figures 6B) and establishes that STAT3 and IRF4 more
broadly functionally cooperate (see Figure S9 for the sequences
spanning the regions in the Socs3,Bcl3, and Tha1 genes that are
depicted in Figure 6B).
We next partitioned the genes into those ‘‘within reach’’ of
either a composite site binding both STAT3 and IRF4, of two
independent sites with one binding STAT3 and the other IRF4,
of a site binding STAT3 or IRF4 alone, or near no candidate
site. Interestingly, genes whose expression was regulated by
IL-21 (>1.5-fold change in the Affymetrix array) were much
more frequently found in the vicinity of composite sites (Table
S8). A chi-square analysis revealed that over the entire genome,
the cooperative binding of STAT3 and IRF4 to the same sites
correlates with a greater propensity to mediate IL-21-induced
regulation of gene expression as compared to sites bindingmmunity 31, 941–952, December 18, 2009 ª2009 Elsevier Inc. 947
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Figure 6. IRF4 Promotes STAT3 Binding
In Vivo
(A) CD4+ T cells from Irf4/ and littermate control
mice were preactivated and rested as in Figure 5A.
mRNA for Socs3, Bcl3, and Tha1 determined by
quantitative RT-PCR 1 and 6 hr after treatment
with 100 ng/ml IL-21. Shown are means ± SEM
of two independent experiments (total combined
samples = 4). *p < 0.05 (compared with WT control
mice).
(B) High-resolution mapping of STAT3 and IRF4-
ChIP-Seq tags in theSocs3,Bcl3, and Tha1 genes.
(C) The distance in base pairs between the precise
position of IRF4 binding, before (blue) or after (red)
IL-21 treatment, and the precise position of STAT3
binding after IL-21 is plotted for all composite
IRF4- and STAT3-binding sites with >30 tags.
(D) CD4+ T cells from Irf4+/+ and Irf4/ mice were
preactivated and stimulated with 100 ng/ml IL-21
as indicated, followed by immunoblotting with
antibodies to phospho-STAT3, STAT3, or Actin.
The representative result of two independent
experiments is shown.
(E) High-resolution mapping of the STAT3 ChIP-
Seq tags in the Prdm1, Socs3, Bcl3, and Tha1
genes in CD4+ T cells from Irf4/ and littermate
control mice.
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Cooperativity of STAT3 and IRF4only STAT3 (p = 3 3 104). Moreover, a chromosomal map de-
picting the location of STAT3 and IRF4 sites throughout the
genome reveals the high frequency of association of IRF4 with
STAT3 and the rarity of apparently functional STAT3 sites that
exist in the absence of IRF4 (Figure S6). Very close binding of
STAT3 with IRF4 was evident in a genome-wide fashion (Fig-
ure 6C). The interesting ‘‘dip’’ in the peak (arrowhead in
Figure 6C) that is evident after IL-21 stimulation suggests steric
constraints when both proteins are present.
IRF4 Promotes STAT3 Binding
Because of the colocalization of STAT3 and IRF4, we investi-
gated whether STAT3 binding is affected by IRF4 deficiency.
We first examined STAT3 phosphorylation and found no
differences in STAT3 phosphorylation in Irf4+/+ and Irf4/
CD4+ T cells after IL-21 treatment (Figure 6D). We next used
ChIP-Seq to map the STAT3-binding sites on the whole genome
in Irf4/ CD4+ T cells. As shown in Figure 6E, binding of STAT3
to the Prdm1, Socs3, Bcl3, and Tha1 genes was greatly dimin-
ished in the absence of IRF4. Moreover, only 14% of the
STAT3-binding sites previously identified (Table S2) were still
present in the Irf4-deficient CD4+ T cells (Table S9), and even
those sites were generally much more weakly seen.948 Immunity 31, 941–952, December 18, 2009 ª2009 Elsevier Inc.IRF4 Is Critical for Tfh Cell
Differentiation
Because STAT3 is a critical mediator for
IL-21-induced follicular helper T (Tfh) cell
differentiation (Nurieva et al., 2008; Vogel-
zang et al., 2008), and we show an IL-21-
induced cooperation of STAT3 and IRF4,
we immunized Irf4/ mice with keyhole
limpet hemocyanin (KLH) to determinethe role of IRF4 in Tfh cell differentiation. The proportion of
KLH-induced CXCR5+ICOS+CD4+ Tfh cells wasmarkedly dimin-
ished in Irf4/ mice, consistent with a role for IRF4 in Tfh cell
differentiation (Figures S8A and S8B). As expected, the propor-
tion of PNA+B220+ germinal center B cells was also low in Irf4/
mice (Figures S8C and S8D).
The TTCnnnTAA Motif that Binds STAT3
in the Prdm1 Gene Is Widely Used
In the Prdm1 IL-21 response element, STAT3 binds to a
TTCnnnTAA variant GAS motif. We thus evaluated the utilization
by STAT3 of the canonical TTCnnnGAA GAS motif versus all
single-nucleotide variants in the 4397 STAT3-binding sites
observed by ChIP-Seq. To evaluate the contribution of each
motif to STAT3 binding, we measured its distance in base pairs
relative to the maximum of the ChIP-Seq tag density and plotted
the distribution of these distances over all STAT3-binding sites;
if a motif binds STAT3, its position should coincide with the
maximum of the tag density. The canonical TTCnnnGAA GAS
motif was the most frequent and best centered (Figure 7A),
and its peak is best approximated by a Gaussian centered at
zero, with an accuracy of a single nucleotide. The TTCnnnTAA/
TTAnnnGAA single-base variant found in the Prdm1 gene was
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B
Figure 7. Distance between the Maxima of
STAT3 Binding and GAS or GAS-like Motifs
(A) The presence of TTCnnnGAA GAS motifs and
single-nucleotide variants in the 4397 STAT3-
binding sites were analyzed genome-wide. The
position of each motif relative to the maximum of
STAT3-binding tags (within 250 bp on each side)
was recorded and the distribution over all sites
was plotted.
(B) Shown are the number of sites with the motif
within 100 bp of maximal STAT3 binding, the
number of observed and expected motifs,
assuming a locally flat distribution, and p value of
the observed overrepresentation of each motif in
the center (Pearson c2 test).
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Cooperativity of STAT3 and IRF4the next best centered, followed by TTCnnnGCA/TGCnnnGAA,
whereas other variants were less well centered. We compared
the number of motifs observed in the central versus the marginal
200 bp of each distribution. Only the top three motifs
(TTCnnnGAA, TTCnnnTAA/TTAnnnGAA, and TTCnnnGCA/
TGCnnnGAA) were markedly enriched in the center of the
binding sites, and we found no evidence for binding to the other
variant motifs (Figure 7B). Thus, the canonical GASmotif and the
TTCnnnTAA and TTCnnnGCA variant motifs are the ones
broadly used for binding STAT3 in response to IL-21.
DISCUSSION
We previously demonstrated that IL-21 augments expression of
BLIMP1, explaining the dramatic ability of IL-21 to drive terminal
B cell differentiation to plasma cells. To explain the basis for
IL-21-induced BLIMP1 expression, we analyzed the Prdm1
gene and identified an IL-21 response element 4.7 kb 30 of
the polyadenylation signal. Importantly, we showed that both
STAT3 and IRF4 bind to this element and are critical for IL-21-
induced Prdm1 expression in B and T cells.
IL-21 is known to signal via STAT3 (Diehl et al., 2008; Zeng
et al., 2007), but a role for IRF4 in IL-21 signaling was not clear.
Irf4 is an immediate early gene induced in B and T cells, but it
also is highly expressed in plasma cells (Klein et al., 2006; Sciam-
mas et al., 2006). Although one group reported that IRF4 is not
required for LPS-induced Prdm1 induction (Klein et al., 2006),Immunity 31, 941–952, Danother showed that Irf4/ B cells have
diminished LPS-induced Prdm1 expres-
sion and detected a putative LPS-
induced IRF4-binding site in intron 5
(Sciammas et al., 2006). A study of
multiple myeloma also found IRF4
binding to the PRDM1 gene (Shaffer
et al., 2008). Although our ChIP-Seq
data reveal IRF4-binding sites within
intron 5 for all IRF4-binding sites inmouse
CD4+ T cells, this region, which is
included in reporter R6, exhibited little if
any IL-21-induced Prdm1 expression.
Instead, the IL-21 response element is 30
of the gene, suggesting that IL-21 and
LPS induce Prdm1 expression via at leastpartially distinct elements, with our data indicating a functional
cooperation between STAT3 and IRF4.
Although IL-21, IL-6, and IL-10 all activate STAT3, their phys-
iological actions differ, presumably as a result of when andwhere
the cytokines are produced and their receptors are expressed.
Additionally, they differ in other signaling pathways used and
other STATs that are activated. For example, IL-21 also activates
STAT1 and STAT5 as well as ERK and PI3-kinase-Akt (Zeng
et al., 2007). In this study, we showed that IL-21 induced
STAT3 phosphorylation more potently than did IL-6 or IL-10,
and correspondingly, IL-21 was the most potent in inducing
Socs3 expression in CD4+ T cells. Socs3 expression was also
IRF4 dependent, suggesting that STAT3 and IRF4 cooperate
for regulating a range of genes.
On the basis of ChIP-Seq analysis, after IL-21 stimulation,
STAT3 binds close to IRF4, not only 30 of the Prdm1 gene but
also at thousands of sites throughout the genome. IRF4 was
frequently bound to sites prior to IL-21 stimulation, suggesting
possibly enhanced binding of STAT3 to IRF4-occupied sites.
Anti-CD3 plus anti-CD28-mediated preactivation of T cells and
anti-CD40 stimulation of B cells can induce Irf4 expression
(Basso et al., 2004; Grumont and Gerondakis, 2000), and consis-
tent with this, the ChIP-Seq data revealed broad IRF4 binding
even before IL-21 treatment and substantial rearrangement of
IRF4 binding after IL-21 treatment. Strikingly, ChIP-Seq analysis
with Irf4/ CD4+ T cells revealed that IL-21-induced STAT3
binding was dramatically diminished, including in the Prdm1,ecember 18, 2009 ª2009 Elsevier Inc. 949
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Cooperativity of STAT3 and IRF4Socs3, Bcl3, and Tha1 genes. Thus, IRF4 is critical for optimal
STAT3 binding after IL-21 treatment in T cells. Our data indicate
that prebound IRF4 may guide STAT3 to specific binding sites
and/or may enhance STAT3 binding. As noted, we were not
able to establish a definitive STAT3-IRF4 physical interaction,
although this cannot be excluded, and it is possible that
additional factors might be required for such an interaction.
Moreover, it is possible that the binding of STAT3 is dependent
on the overall chromatin structure and that the presence of
IRF4 alters this structure to allow and/or facilitate the binding
of STAT3.
IRF4 was previously shown to be critical for Th2 (Lohoff et al.,
2002) and Th17 (Bru¨stle et al., 2007) cell differentiation. Consis-
tent with IRF4 cooperatively acting with STAT3, which is known
to be important for IL-21-induced Tfh cell differentiation (Nurieva
et al., 2008; Vogelzang et al., 2008), our data indicate that IRF4
may also contribute to Tfh cell differentiation.
In summary, we have identified an IL-21 response element 30
to the Prdm1 gene that binds STAT3 and IRF4, and we show a
functional cooperation between these two proteins. ChIP-Seq
genome wide analysis revealed that this effect is not restricted
to the Prdm1 gene, establishing the broad importance of
STAT3-IRF4 cooperation. We further show defective Tfh cell
differentiation in Irf4/mice analogous to the reported defective
Tfh cell differentiation in Stat3/mice. Whether there is broader
cooperativity of other STAT proteins with IRF4 or of STAT3 with
other IRF family members is an area for future investigation.
Finally, we have elucidated the relative utilization of canonical
versus noncanonical GAS motifs for STAT3 binding in vivo and
demonstrated broad use of a variant motif that is critical in the
Prdm1 IL-21 response element.
EXPERIMENTAL PROCEDURES
Mice and Cell Culture
Animal experiments used protocols approved by the NHLBI Animal Use and
Care Committee and followed NIH guidelines. Details of mice and cell culture
are provided in the Supplemental Experimental Procedures.
Preactivation of Cells and Cytokines
For preactivation of CD4+ T cells, cells were stimulated with 3 mg/ml plate-
bound anti-CD3, 1 mg/ml soluble anti-CD28, and 50 U/ml IL-2 for 3 days and
rested for 24 hr in fresh RPMI medium. Cytokines were used at the following
concentrations: 100 U/ml IL-2, 50 ng/ml IL-4, 10 ng/ml IL-5, 10 ng/ml IL-6,
20 ng/ml IL-10, 100 ng/ml IL-21, or 50 ng/ml IFN-g.
Antibodies
Antibodies to STAT3, STAT5A, and STAT5B were from Zymed (South San
Francisco, CA), antibodies to STAT1, IRF4, IRF8, and PU.1 were from Santa
Cruz (Santa Cruz, CA), and antibodies to CD33 and CD28 were from PharMin-
gen (San Diego, CA).
Quantitative Real-Time PCR Analysis
This was performed with standard methods (see Supplemental Experimental
Procedures).
Immunoblotting and FACS
For immunoblotting (Kovanen et al., 2008), cell lysates were resolved on 10%
Bis-Tris gels (NuPAGE) and immunoblotted with antibodies to phospho-
STAT3 (Cell Signaling Technology, CA), STAT3 (PharMingen, CA), BLIMP1
(Novus, CO), and b-actin (Santa Cruz, CA). FACSwas performedwith standard
methods.950 Immunity 31, 941–952, December 18, 2009 ª2009 Elsevier Inc.Enhancer Constructs, Transient Transfections,
and Luciferase Assays
Themouse979 and +183Prdm1 promoter fragment was cloned between the
HindIII and XhoI polylinker sites in pGL3-Basic or pGL4-Basic luciferase
reporter vectors (Promega, Madison, WI) (Supplemental Experimental Proce-
dures). A total of 5 3 106 NFS201 cells were transfected with 5 mg of test
plasmid and 40 ng of pRL-TK as a transfection efficiency control, with use of
the DEAE-dextran method. Twenty-four hours later, cells were stimulated
with medium or 50 ng/ml of mouse IL-21 (R&D Systems) for 18 hr. Splenic B
cells, CD4+ T cells, or CD8+ T cells were isolated from 6- to 8-week-old
C57BL/6 mice with anti-B220, anti-CD4, or anti-CD8-microbeads (Miltenyi).
B cells were preactivated with 1 mg/ml anti-CD40 for 3 days, rested for
24 hr, and electroporated (Electropulser, Bio-Rad) with 20 mg of test plasmid
and 10 mg of pRL-TK. Splenic CD4+ and CD8+ T cells were activated with
plate-bound anti-CD33 (3 mg/ml), soluble anti-CD28 (1 mg/ml), and IL-2
(50 U/ml) for 3 days, rested for 24 hr, and electroporated with 10 mg of test
plasmid and 5 mg pRL-TK. B and T cells were rested, stimulated with medium
or 100 ng/ml mouse IL-21 for 6 hr, and analyzed for luciferase activity with a
luminometer (Victor2 1420 Multilabel Counter; PerkinElmer Life Sciences)
and a Dual Luciferase Assay System Kit (Promega).
Electrophoresis Mobility Shift Assays and Chromatin
Immunoprecipitation Assays
These were done by standard methods (see Supplemental Experimental
Procedures).
ChIP-Seq Analysis
CD4+ T cells were prepared and ChIP-Seq data were generated as described
previously (Schones et al., 2008). A matched IgG control was associated to
each experiment. Chromatin from 107 cells (200 ng of DNA) was sonicated
into 200–500 bp fragments, DNA ends were repaired with polynucleotide
kinase and Klenow enzyme and treated with Taq polymerase for generation
of a protruding 30 ‘‘A’’ nucleotide for adaptor ligation. After ligation of Solexa
adaptors, DNA was amplified with the adaptor primers for 17 cycles and
fragments of 220 bp (mononucleosome + adaptors) were isolated from
agarose gels and used for cluster generation and sequencing on a Solexa
1G and Illumina GA2 Genome Analyzers. The sequence tags will be available
from the NCBI Trace/Short Read Archive repository. To align sequence tags,
analyze their clustering, identify binding motifs, and display results, we devel-
oped new code in C language as extensions of the AceView project (Thierry-
Mieg and Thierry-Mieg, 2006). Each Solexa 25-mer tag was mapped on the
mouse reference genome (version 37), allowing up to two mismatches
(single-base insertion, deletion, or substitution), and retained only if it had
a single best position genome-wide. Each tag was shifted downstream by
half the effective length of the sonicated sequenced fragments, measured as
the maximum of the genome-wide correlation function between hits to the
sense and antisense strands of the chromosomes, and represented by
a Gaussian with an area of 1 and s of 100 bp, which dampens the sampling
fluctuations and introduces a controlled level of fuzziness and ‘‘smoothness.’’
Summing these elementary Gaussians yields a smoothed tag density. Regions
where the density locally exceeds a given threshold are analyzed. The number
of tags was measured after subtracting the local tags from the matched IgG
experiment. If the tag number exceeded a second threshold, it was scored
as a peak. Regions with an IgG peak were deemed nonspecific and eliminated.
The peak height indicates the protein binding strength. The position of the
peak maximum (i.e., the maximum of the probability of binding the protein)
is expected to coincide with the binding motif. The width covered by the
peak (typically 200–600 bp) is the region protected by the protein or protein
complex. Often, in large peaks, one can distinguish subpeaks, which probably
correspond to the binding of multiple proteins. When multiple proteins bind to
overlapping sequences, their peaks are clustered to generate a broader
composite binding site. See Supplemental Experimental Procedures and
Figures S4, S5, and S6 for details.
RNA Preparation and Microarray Analysis
Total RNA was prepared with RNeasy (QIAGEN, Valencia, CA). Probes were
prepared with Affymetrix protocols and hybridized to mouse MOE 430
Immunity
Cooperativity of STAT3 and IRF42.0 arrays (Affymetrix, Santa Clara, CA). The excellent reproducibility across
replicas is shown in Figure S2.
ACCESSION NUMBERS
The microarray primary CEL files and Illumina raw Chip-Seq data are available
in the Gene Expression Omnibus (GEO) database (http://www.ncbi.nlm.nih.
gov/gds) under the accession number GSE19198.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures, nine
figures, and eleven tables and can be found with this article online at http://
www.cell.com/immunity/supplemental/S1074-7613(09)00511-1.
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